Evidence map›Paper›PMID 40443825›Full record

ArticleACS applied nano materials2024

Glycopolymeric Nanoparticles Block Breast Cancer Growth by Inhibiting Efferocytosis in the Tumor Microenvironment.

Oluwaseyi Shofolawe-Bakare, Veeresh B Toragall, Kenneth Hulugalla, Railey Mayatt, Paige Iammarino, John P Bentley, Adam E Smith, Thomas Werfel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied nano materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Oluwaseyi Shofolawe-BakareDepartment of Chemical Engineering, University of Mississippi, University, MS, USA, 38677.
Veeresh B ToragallDepartment of Biomedical Engineering, University of Mississippi, University, MS, USA, 38677.
Kenneth HulugallaDepartment of BioMolecular Sciences, University of Mississippi, University, MS, USA, 38677.
Railey MayattDepartment of Chemistry, Mississippi State University, Starkville, MS, USA. 39762.
Paige IammarinoInstitute for Imaging and Analytical Technologies, Mississippi State University, Starkville, MS, USA, 39762.
John P BentleyDepartment of Pharmacy Administration, University of Mississippi, University, MS, USA, 38677.
Adam E SmithDepartment of Chemical Engineering, University of Mississippi, University, MS, USA, 38677.
Thomas WerfelDepartment of Chemical Engineering, University of Mississippi, University, MS, USA, 38677.

Funding

Training and Mentoring Core P20GM103476 · NIGMS · UNIVERSITY OF SOUTHERN MISSISSIPPI · PI MICHAEL R GARRETT · 2012 to 2026
$60.2M
Tracking Glycosylation State with Fluorinated Glycosides ProbesP20GM130460 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI Joshua S Sharp · 2020 to 2026
$17.9M
Laser spectroscopic instrumentation for isotopic sensing of biogenic Nitric OxideR21GM103460 · NIGMS · PRINCETON UNIVERSITY · PI WYSOCKI, GERARD · 2012 to 2012
$190k
NIGMS NIH HHS P20 GM103476NIGMS NIH HHS P20 GM130460NIGMS NIH HHS R21 GM103460
6 · The paper itself

Abstract

Conventional inhibitors of immune checkpoints such as anti-programmed death-1 and its ligand (anti-PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA4) have revolutionized therapeutic approaches to cancer, establishing immunotherapy as the standard of care for many cancers. A significant number of cancers, however, remain refractory to the inhibition of these immune checkpoints, leading to the search for alternative immune checkpoints that are more relevant to those diseases. Tumor-associated macrophage (TAM)-mediated efferocytosis is an increasingly appreciated immune checkpoint with a profound impact on the phenotype of the tumor microenvironment (TME). TAMs perform their efferocytic function through the receptor MerTK, and MerTK activity correlates with tumor progression. To combat efferocytosis in the TME, we developed poly[[2-(diisopropylamino)ethyl methacrylate]-

Indexed as

Cancer ImmunotherapyDrug DeliveryEfferocytosisGlycopolymerTumor-Associated Macrophages

Identifiers

PMID40443825
PMCPMC12121950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.